Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib

Journal of Veterinary Pharmacology and Therapeutics

Volumn 32, Issue 1, 2009, Pages 31-40

  Giraudel, J M ^a,d   Toutain, P L ^b   King, J N ^c   Lees, P ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Novartis Centre de Recherche Santé Animale SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM IONOPHORE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; LIPOPOLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ROBENACOXIB; THROMBOXANE B2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SPECIFICITY; ENZYME INHIBITION; FEMALE; IC 50; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE;

ANIMALIA; FELIDAE;

EID: 58449099562     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2008.01031.x     Document Type: Article

References (46)

1. Armstrong, S. Lees, P. (2002) Effects of carprofen (R and S enantiomers and racemate) on the production of IL-1, IL-6 and TNF-alpha by equine chondrocytes and synoviocytes. Journal of Veterinary Pharmacology and Therapeutics, 25, 145 153.
2. Blain, H., Boileau, C., Lapicque, F., Nedelec, E., Loeuille, D., Guillaume, C., Gaucher, A., Jeandel, C., Netter, P. Jouzeau, J.Y. (2002) Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. British Journal of Clinical Pharmacology, 53, 255 265.
3. Botting, R.M. (2000) Paracetamol-inhibitable COX-2. Journal of Physiological Pharmacology, 52, 609 618.
4. Brideau, C., Kargman, S., Liu, S., Dallob, A.L., Ehrich, E.W., Rodget, I.W. Chan, C.C. (1996) A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflammation Research, 45, 68 74.
5. Capone, M.L., Tacconelli, S., Sciulli, M.G. Patrignani, P. (2003) Clinical pharmacology of selective COX-2 inhibitors. International Journal of Immunopathology and Pharmacology, 16, 49 58.
6. Chen, X.H., Bai, J.Y., Shen, F., Bai, A.P., Guo, Z.R. Cheng, G.F. (2004) Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacologica Sin, 25, 927 931.
7. Coruzzi, G., Menozzi, A. Dobrilla, G. (2004) Novel non-steroidal anti-inflammatory drugs: what we have learned from animal studies. Current Drug Targets in Inflammation and Allergy, 3, 43 61.
8. Cryer, B. Feldman, M. (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. American Journal of Medicine, 104, 413 421.
9. Dallob, A., Hawkey, C.J., Greenbergh, H., Wight, N., De Schepper, P., Waldman, S., Wong, P., DeTora, L., Gertz, B., Agrawal, N., Wagner, J. Cottesdiener, K. (2003) Characterization of etoricoxib, a novel, selective COX-2 inhibitor. Journal of Clinical Pharmacology, 43, 573 585.
10. Demasi, M., Caughey, G.E., James, M.J. Celeland, L.G. (2000) Assay of cyclooxygenase-1 and 2 in human monocytes. Inflammation Research, 49, 737 743.
11. Dieter, P., Scheibe, R., Jakobsson, P.J., Watanabe, K., Kolada, A. Kamionka, S. (2000) Functional coupling of cyclooxygenase 1 and 2 to discrete prostanoid synthases in liver macrophages. Biochemical and Biophysical Research Communications, 276 488 492.
12. Duffy, T., Belton, O., Bresnihan, B., Fitzgerald, O. Fitzgerald, D. (2003) Inhibition of PGE2 production by nimesulide compared with diclofenac in the acutely inflamed joint of patients with arthritis. Drug, 63 (Suppl. 1 31 36.
13. Gilroy, D.W., Lawrence, T., Perretti, M. Rossi, A.G. (2004) Inflammatory resolution: new opportunities for drug discovery. Nature Reviews, Drugs Discovery, 3, 401 416.
14. Giraudel, J.M., Toutain, P.L. Lees, P. (2005) Development of in vitro assays for the evaluation of cyclooxygenase inhibitors and predicting selectivity of nonsteroidal anti-inflammatory drugs in cats. American Journal of Veterinary Research, 66, 700 709.
15. Giraudel, J.M., King, J.N., Jeunesse, E.C., Lees, P. Toutain, P.L. (2009) Use of a pharmacokinetic/pharmacodynamic approach in the cat to the determination of a dosage regimen for the COX-2 selective drug robenacoxib. Journal of Veterinary Pharmacology and Therapeutics, 32, 18 30.
16. Giuliano, F. Warner, T.D. (1999) Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. British Journal of Pharmacology, 126, 1824 1830.
17. Giuliano, F. Warner, T.D. (2002) Origins of prostaglandin E2: involvements of cyclooxygenase (COX)-1 and COX-2 in human rat systems. Journal of Pharmacology and Experimental Therapeutics, 303, 1001 1006.
18. Giuliano, F., Ferraz, J.G., Pereira, R., de Nucci, G. Warner, T.D. (2001) Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. European Journal of Pharmacology, 426, 95 103.
19. Griswold, D.E. Adams, J.L. (1996) Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Medicine Research Reviews, 16, 181 206.
20. Higgins, A.J. Lees, P. (1984) Arachidonic acid metabolites in carrageenin-induced equine inflammatory exudate. Journal of Veterinary Pharmacology and Therapeutics, 7, 65 72.
21. Jung, M., Lees, P., Seewald, W. King, J.N. (2009) Analytical determination and pharmacokinetics of robenacoxib in the dog. Journal of Veterinary Pharmacology and Therapeutics, 32, 41 48.
22. King, J.N., Dawson, J., Esser, R.E., Fujimoto, R., Kimble, E.F., Manara, W., Marshall, P.J., O'Bryrne, L.O., Quadros, E., Toutain, P.L. Lees, P. (2009) Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooygenase-2. Journal of Veterinary Pharmacology and Therapeutics, 32, 1 17.
23. Kujubu, D.A., Fletcher, B.S., Varnum, B.C., Lim, R.W. Herschman, H.R. (1991) TIS 10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. Journal of Biological Chemistry, 266, 12866 12872.
24. Landoni, M.F., Cunningham, F.M. Lees, P. (1995) Comparative pharmacodynamics of flunixin, ketoprofen and tolfenamic acid in calves. Veterinary Record, 137, 428 431.
25. Landoni, M.F., Comas, W., Mucci, N., Anglarilli, G., Bidal, D. Lees, P. (1999) Enantiospecific pharmacokinetics and pharmacodynamics of ketoprofen in sheep. Journal of Veterinary Pharmacology and Therapeutics, 22, 349 359.
26. Laneuville, O., Breuer, D.K., Dewitt, D.L., Hla, T., Funk, C.D. Smith, W.L. (1994) Differential inhibition of human prostaglandin endoperoxide H synthases-1 and 2 by nonsteroidal anti-inflammatory drugs. Journal of Pharmacology and Experimental Therapeutics, 271, 927 934.
27. Lees, P. (2003) Pharmacology of drugs used to treat osteoarthritis in veterinary practice. Inflammopharmacology, 11, 385 399.
28. Lora, M., Denault, J.B., Leduc, R. De Brum-Fernandes, A.J. (1998) Systematic pharmacological approach to the characterization of NSAIDs. Prostaglandins Leukotrienes and Essential Fatty Acids, 59, 55 62.
29. Matsumoto, H., Naraba, H., Murakami, M., Kudo, I., Yamaki, K., Ueno, A. Oh-Ishi, S. (1997) Concordant induction of prostaglandin E2 synthase with cyclooxygenase-2 leads to preferred production or prostaglandin E2 over thromboxane and prostaglandin D2 in lipopolysaccharide-stimulated rate peritoneal macrophages. Biochemical and Biophysical Research Communications, 230, 110 114.
30. Mukherjee, A., Hale, V.G., Borga, O. Stein, R. (1996) Predictability of the clinical potency of NSAIDs from the preclinical pharmacodynamics in rats. Inflammation Research, 45, 531 540.
31. Pairet, M. Van Ryn, J. (1998) Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflammation Research, 47 (Suppl 2 S93 S101.
32. Panara, M.R., Padovano, R., Sciulli, M.G., Santini, G., Renda, G., Rotondo, M.T., Pace, A., Patrono, C. Patrignani, P. (1998) Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings. Clinical Pharmacology and Therapeutics, 63, 672 681.
33. Panara, M.R., Renda, G., Sciulli, M.G., Santini, G., Di Giamberardino, M., Rotondo, M.T., Tacconelli, S., Seta, F., Patrono, C. Patrignani, P. (1999) Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. Journal of Pharmacology and Experimental Therapeutics, 290, 276 280.
34. Patrignani, P., Panara, M.R., Greco, A., Fucso, O., Natoli, C., Iacobelli, S., Cipollone, F., Ganci, A., Creminon, C. Macloud, J. (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. Journal of Pharmacology and Experimental Therapeutics, 271, 1705 1712.
35. Patrignani, P., Panara, M.R., Sciulli, M.G., Santini, G., Renda, G. Patrono, C. (1997) Differential inhibition of human prostanglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. Journal of Physiological Pharmacology, 48, 623 631.
36. Riendeau, D., Percival, M.D., Brideau, C., Charleson, S., Dube, D., Ethier, D., Falgueyret, J.P., Friesen, R.W., Gordon, R., Greig, G., Guay, J., Mancini, J., Quellet, M., Wong, E., Xu, L., Boyce, S., Visco, D., Girard, Y., Prasit, P., Zamboni, R., Rodget, I.W., Gresser, M., Ford-Hutchinson, A.W., Young, R.N. Chan, C.C. (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. Journal of Pharmacology and Experimental Therapeutics, 296, 558 566.
37. Simmons, D.L., Botting, R.M., Robertson, P.M., Madsen, M.L. Vane, J.R. (1999) Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroidal anti-inflammatory drugs. Proceedings of the National Academy of Sciences, 96, 3275 3280.
38. 2 inhibits multiple steps in the NF-kB signalling pathway. Proceedings of the National Academy of Sciences, 97, 4844 4849.
39. Swinney, D.C., Mak, A.Y., Barnett, J. Ramesha, C.S. (1997) Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid. Journal of Biological Chemistry, 272, 12393 12398.
40. Taylor, P.M., Delatour, P., Landoni, F.M., Deal, C., Pickett, C., Shojaee AliAbadi, F., Foot, R. Lees, P. (1996) Pharmacodynamics and enantioselective pharmacokinetics of carprofen in the cat. Research in Veterinary Science, 60, 144 151.
41. Torres-Lopez, J.E., Robles, M.B., Perez-Urizar, J., Flores-Murrieta, F.J. Granados-Soto, V. (1997) Determination of declofenac in micro-whole blood samples of high-performance liquid chromatography with electrochemical detection. Application in a pharmacokinetic study. Arzneimittel-Forschung, 47, 1040 1043.
42. Toutain, P.L., Cester, C.C., Haak, T. Metge, S. (2001) Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. Journal of Veterinary Pharmacology and Therapeutics, 24, 35 42.
43. Walker, M.C., Kurumbail, R.G., Kiefer, J.R., Moreland, K.T., Koboldt, C.M., Isakson, P.C., Seibert, K. Gierse, J.K. (2001) A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochemical Journal, 357, 709 718.
44. Wallace, J.L. (1999) Selective COX-2 inhibitors: is the water becoming muddy? Trends in Pharmacological Sciences, 20, 4 6.
45. Waver, M.L., Flood, D.J., Kimble, E.F. Fukimoto, R.A. (2003) Lumiracoxib demonstrates preferential distribution to inflamed tissue in the rat following a single oral dose: an effect not seen with other cyclo-oxygenase-2 inhibitors. Annals of Rheumatic Diseases, 62 (Suppl 2 538.
46. Wearner, T.D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J.A. Vane, J.R. (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proceedings of the National Academy of Sciences, 96, 7563 7568.